These are preliminary reports that have not been peer-reviewed. They should not be regarded as conclusive, guide clinical practice/health-related behavior, or be reported in news media as established information. For more information, please see our FAQs.
2 files

Nature as a Treasure Trove for Anti-COVID-19: Luteolin and Naringenin from Indonesian Traditional Herbal Medicine Reveal Potential SARS-CoV-2 Mpro Inhibitors Insight from in Silico Studies

submitted on 10.12.2020, 02:39 and posted on 11.12.2020, 06:27 by Wahyu Prasetyo, Triana Kusumaningsih, Maulidan Firdaus
Since the worldwide is currently facing the COVID-19 pandemic, there are no drugs or vaccines have been approved
for the treatment of SARS-CoV-2 infection. Therefore, there is an urgent need for in-depth research on emerging
human infectious coronaviruses. As part of our endeavour in combating this COVID-19 pandemic, in this paper, we
report on the discovery of an active antiviral small-molecule from Indonesian traditional herbal medicine used in Jamu
to inhibit 3CLpro of SARS-CoV-2 using in-silico approaches. As one of the mega biodiversity countries, Indonesia has
more than 1,180 species that can be prospected for medicine plants. Jamu, the Indonesian traditional herbal medicine,
is supposed to have similar potentials as those of traditional Chinese medicine (TCM). However, due to the lack of
scientific proof, Jamu is not recognised in the Guideline of COVID-19 Patients, particularly in Indonesia. Thus, in
this study, we performed virtual docking screening along with pharmacokinetic and DFT studies of selected 49
bioactive phytochemicals from several medicinal plants used in Jamu against the 3CLpro enzyme of SARS-CoV-2.
From the result, it was noted that from a set of 49 phytochemicals of medicinal plants used in Jamu, 2 phytochemicals,
i.e., Luteolin and Naringenin were identified as potential druggable inhibitors candidates of 3CLpro of SARS CoV-2.


Email Address of Submitting Author


Sebelas Maret University



ORCID For Submitting Author


Declaration of Conflict of Interest

no conflict of interest